<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol Immunother</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy : CII</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40402266</article-id><article-id pub-id-type="pmc">PMC12098241</article-id>
<article-id pub-id-type="publisher-id">4032</article-id><article-id pub-id-type="doi">10.1007/s00262-025-04032-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Reischer</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0003-3069-3733</contrib-id><name><surname>Leutbecher</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hiller</surname><given-names>Bj&#x000f6;rn</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Perini</surname><given-names>Enrico</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Kieron</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hern&#x000e1;ndez-C&#x000e1;ceres</surname><given-names>Alejandra</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Schele</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tast</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rohrbacher</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Winter</surname><given-names>Lis</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Czogalla</surname><given-names>Bastian</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mahner</surname><given-names>Sven</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Flaswinkel</surname><given-names>Heinrich</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Leonhardt</surname><given-names>Heinrich</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wyder</surname><given-names>Lorenza</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wichmann</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Maenner</surname><given-names>Denis</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Trillsch</surname><given-names>Fabian</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kessler</surname><given-names>Mirjana</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4528-8357</contrib-id><name><surname>Hopfner</surname><given-names>Karl-Peter</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Fenn</surname><given-names>Nadja C.</given-names></name><address><email>nfenn@genzentrum.lmu.de</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9154-9469</contrib-id><name><surname>Subklewe</surname><given-names>Marion</given-names></name><address><email>marion.subklewe@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Department of Medicine III, University Hospital, </institution><institution>LMU Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Laboratory of Translational Cancer Immunology, </institution><institution>LMU Gene Center, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Gene Center and Department of Biochemistry, </institution><institution>LMU Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Department of Obstetrics and Gynecology, </institution><institution>Comprehensive Cancer Center Munich, University Hospital, LMU Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Faculty of Biology and Center for Molecular Biosystems (BioSysM), Human Biology and BioImaging, </institution><institution>LMU Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jet3w32</institution-id><institution-id institution-id-type="GRID">grid.411095.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0477 2585</institution-id><institution>Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, </institution><institution>University Hospital, LMU Munich, </institution></institution-wrap>Munich, Germany </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><volume>74</volume><issue>7</issue><elocation-id>214</elocation-id><history><date date-type="received"><day>24</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The immune checkpoint CD47 is highly upregulated in several cancers as an innate immune escape mechanism. CD47 delivers a &#x0201c;don&#x02019;t eat me&#x0201d; signal to its co-receptor signal regulatory protein&#x000a0;&#x003b1; (SIRP&#x003b1;), thereby inhibiting phagocytosis. Blocking the CD47&#x02013;SIRP&#x003b1; axis is a promising immunotherapeutic strategy against cancer. However, early trial data has demonstrated on-target off-leukemia toxicity. In addition, the ubiquitous expression pattern of CD47 might contribute to an antigen sink. In this study, we combined low-affinity CD47 checkpoint blockade and specific tumor targeting in a multivalent and multifunctional antibody construct to prevent CD47-related toxicities. First, we established a local inhibitory checkpoint monoclonal antibody (LicMAb) by fusing two <italic>N</italic>-terminal extracellular domains of SIRP&#x003b1; to a full-length anti-human mesothelin (MSLN)-IgG1 antibody, a well-described tumor-associated antigen in epithelial ovarian cancer (EOC) and pancreatic ductal adenocarcinoma (PDAC). Next, we evaluated the SIRP&#x003b1;-&#x003b1;MSLN LicMAb for mediating a tumor-restricted immune response as observed by antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). Our data validates CD47 and MSLN as highly upregulated targets expressed on various solid cancer entities, particularly EOC. We show tumor-specific binding and CD47 blocking by the SIRP&#x003b1;-&#x003b1;MSLN LicMAb even in the presence of healthy CD47-expressing cells. Furthermore, the LicMAb induces NK-cell-mediated cytotoxicity and improves phagocytosis of EOC and PDAC tumor cells. Moreover, cell death in EOC-derived organoids was specifically LicMAb-driven. Hence, the SIRP&#x003b1;-&#x003b1;MSLN LicMAb combines a tumor-restricted blockade of the CD47&#x02013;SIRP&#x003b1; axis with a specific antitumor response while preventing on-target off-tumor toxicities. Our data supports the multifunctional SIRP&#x003b1;-&#x003b1;MSLN LicMAb as a promising approach to treating solid tumors.</p><sec><title>Graphical abstract</title><p id="Par2">
<graphic position="anchor" xlink:href="262_2025_4032_Figa_HTML" id="MO1"/>
</p><p id="Par3">The local inhibitory checkpoint monoclonal antibody (LicMAb) binds mesothelin (MSLN) with high affinity and simultaneously blocks CD47 on MSLN-expressing tumor cells to inhibit the &#x0201c;don&#x02019;t eat me&#x0201d; signal. CD47 is blocked by the fused extracellular SIRP&#x003b1; domain that intrinsically has a low affinity. Furthermore, the SIRP&#x003b1;-&#x003b1;MSLN LicMAb is based on a human IgG1 backbone to provide an Fc receptor (FcR)-activating stimulus to enable direct NK-cell-mediated killing by granzyme B (GrzB) and perforin secretion, and an additional pro-phagocytic signal to phagocytic cells, such as macrophages (M&#x000d8;). This leads to tumor-restricted antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) of cancer cells. This scheme was created with BioRender (BioRender.com/g77u465).</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00262-025-04032-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>CD47&#x02013;SIRP&#x003b1;</kwd><kwd>Innate immune checkpoints</kwd><kwd>Mesothelin</kwd><kwd>Multifunctional antibodies</kwd><kwd>Solid tumors</kwd></kwd-group><funding-group><award-group><funding-source><institution>Else-Kr&#x000f6;ner-Fresenius Forschungskolleg CSP Cancer Immunotherapy</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Bavarian Elite Graduate School "i-target"</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Sonderforschungsbereich SFB</institution></funding-source><award-id>338</award-id><award-id>338</award-id><principal-award-recipient><name><surname>Winter</surname><given-names>Lis</given-names></name><name><surname>Subklewe</surname><given-names>Marion</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Deutsche Forschungsgemeinschaft (DFG)</institution></funding-source><award-id>451580403</award-id><award-id>451580403</award-id><principal-award-recipient><name><surname>Hopfner</surname><given-names>Karl-Peter</given-names></name><name><surname>Subklewe</surname><given-names>Marion</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Exist Transfer of Research I grant</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Klinikum der Universit&#x000e4;t M&#x000fc;nchen (6933)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par40">Immunotherapy has revolutionized the therapeutic landscape of oncology for most tumor entities. In recent decades, monoclonal antibodies (mAbs) targeting immune checkpoints have reformed treatment algorithms for various cancer entities [<xref ref-type="bibr" rid="CR1">1</xref>]. However, some solid cancer entities such as epithelial ovarian cancer (EOC) or pancreatic ductal adenocarcinoma (PDAC) show only limited response to the blockade of adaptive immune checkpoint inhibitors (ICIs). As the patient outcome remains poor in these disease entities, novel treatment options are highly sought after [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par41">The inhibitory innate checkpoint molecule CD47 is known as a &#x0201c;marker of self&#x0201d; and is expressed on almost every cell in the body. The interaction of CD47 with its co-receptor signal inhibitory regulatory protein &#x003b1; (SIRP&#x003b1;) on phagocytes sends a &#x0201c;don&#x02019;t eat me&#x0201d; signal that is necessary for healthy homeostasis, especially in the life cycle of red blood cells (RBCs) [<xref ref-type="bibr" rid="CR4">4</xref>]. Interestingly, CD47 has been reported to be overexpressed in many different hematological and solid tumors as an immune escape mechanism [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par42">Targeting CD47 with mAbs has been shown to block the CD47&#x02013;SIRP&#x003b1; signaling axis and thus, leads to enhanced phagocytosis of tumor cells. The first-in-class IgG4 CD47-targeting mAb magrolimab, followed by others, demonstrated robust anti-cancer activity in patients with hematologic and solid cancers [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Nevertheless, as CD47 is ubiquitously expressed on healthy cells, its targeting leads to CD47-induced toxicities, such as anemia and thrombocytopenia [<xref ref-type="bibr" rid="CR9">9</xref>]. Additionally, high doses of CD47-targeting mAbs are required due to a large antigen sink [<xref ref-type="bibr" rid="CR8">8</xref>]. Clinical trials with magrolimab in hematologic and solid malignancies were discontinued due to on-target off-tumor toxicity rendering further investigation futile (e.g. NCT05079230, NCT06046482). To reduce CD47 targeting on healthy cells, other strategies to block the CD47&#x02013;SIRP&#x003b1; axis were developed such as &#x003b1;CD47 mAbs with reduced RBC targeting [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>] or SIRP&#x003b1; fusion proteins [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. The overall concept of the CD47 blockade has been proven more effective when combined with a pro-phagocytic stimulus, such as rituximab, an &#x003b1;CD20 IgG1 mAb [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par43">One strategy to combine the benefits of a tumor-restricted CD47 blockade with a pro-phagocytic stimulus in a single molecule is to fuse SIRP&#x003b1; with a tumor-associated antigen (TAA)-specific IgG1 antibody. This approach has been validated preclinically in hematologic malignancies [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par44">The TAA mesothelin (MSLN) is highly expressed in several solid cancer types, particularly in EOC, PDAC, and mesothelioma [<xref ref-type="bibr" rid="CR18">18</xref>]. Hence, to improve the treatment options for these disease entities, we fused the endogenous SIRP&#x003b1; immunoglobulin V-like domain to the <italic>N</italic>-terminus of the light chain of an anti-human MSLN IgG1 mAb generating a SIRP&#x003b1;&#x02013;&#x003b1;MSLN local inhibitory checkpoint monoclonal antibody (LicMAb).</p><p id="Par45">Our in vitro studies demonstrated successful clearance of MSLN-expressing cancer cells by IgG1-mediated activation of innate immune cells inducing cytotoxicity and phagocytosis. Moreover, we confirmed the preclinical efficacy of SIRP&#x003b1;-&#x003b1;MSLN LicMAb in primary EOC samples and patient-derived organoids.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>RNAseq and genomic alteration analysis</title><p id="Par46">Transcriptomic data and corresponding clinical data from the Cancer Genome Atlas PanCancer Studies data collection (TCGA-PanCancer Atlas) were downloaded from cBioportal (<ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org">https://www.cbioportal.org</ext-link><underline>)</underline>. Samples were filtered based on the availability of mRNA expression data (n&#x02009;=&#x02009;10,071 samples, 91% of TCGA-PanCancer Atlas cohort). mRNA expression z-scores relative to all samples (log RNAseq V2 RSEM) were used to assess the expression of MSLN and CD47 across cancer types. The cancer types and relative sample numbers are described in Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>. The package ggplot2 tool in R was used for data visualization. To assess the genomic changes across cancer types, MSLN and CD47 were manually selected. Within the cBioportal visualization tool, &#x0201c;Mutation count&#x0201d; and &#x0201c;Genes with the highest frequency in any group&#x0201d; were selected. The mutation count for each cancer type was plotted on a boxplot and the 10 most frequently mutated genes for each cancer type were plotted on a bar graph.</p></sec><sec id="Sec4"><title>Generation of local inhibitory checkpoint monoclonal antibody (LicMAb)</title><p id="Par47">Human MSLN antibodies were generated by immunizing mice and rats with the extracellular domain of MSLN (amino acids 296&#x02013;606). A detailed description of the SIRP&#x003b1;-&#x003b1;MSLN LicMAb generation is provided in the supplementary methods. In brief, RNA was isolated from hybridoma cells, variable light (V<sub>L</sub>) and variable heavy (V<sub>H</sub>) chains were amplified, and genes were synthesized and cloned into expression vectors containing the constant human IgG1 framework. The <italic>N</italic>-terminal Ig&#x000a0;V-like domain of SIRP&#x003b1; was linked to the &#x003b1;MSLN light chain by a flexible polyglycine&#x02013;serine four-repeat linker (G<sub>4</sub>S)<sub>4</sub> to clone a SIRP&#x003b1;-&#x003b1;MSLN LicMAb. All proteins were produced in Expi293F cells and purified. The &#x003b1;CD33 mAb and SIRP&#x003b1;-&#x003b1;CD33 LicMAb, as well as high-affinity &#x003b1;CD47 IgG4 and &#x003b1;CD47 IgG1 mAb (h5F9-G4 and h5F9-G1, respectively), served as controls.</p></sec><sec id="Sec5"><title>Antibody-dependent cellular cytotoxicity (ADCC)</title><p id="Par48">For the impedance-based readout, target cells were seeded in a sterile 96-well real-time cell analysis (RTCA) E-plate (Agilent) and cultured in the xCELLigence (Agilent) for 24&#x000a0;h. NK cells were isolated from fresh peripheral blood mononuclear cells (PBMCs) using the human NK Cell Isolation Kit (Miltenyi Biotec). NK cells were co-cultured with target cells and antibodies for 24&#x000a0;h. Cytotoxicity was calculated after 4&#x000a0;h of co-culture as <inline-formula id="IEq1"><alternatives><tex-math id="d33e653">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\text{overall lysis }[\%]=\{1-(\text{normalized cell index of condition})/(\text{normalized cell index of condition w}/\text{o Ab})\}\times 100$$\end{document}</tex-math><mml:math id="d33e658"><mml:mrow><mml:mtext>overall lysis</mml:mtext><mml:mspace width="0.333333em"/><mml:mo stretchy="false">[</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>normalized cell index of condition</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>normalized cell index of condition w</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>o Ab</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">}</mml:mo><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_4032_Article_IEq1.gif"/></alternatives></inline-formula>. For the multiparametric flow cytometry (MPFC)-based readout, isolated NK cells were co-cultured with CellTrace CFSE-labeled target cells and antibodies for 4&#x000a0;h. Cells were stained with LIVE/DEAD Near-IR Dead Cell Staining Kit (Invitrogen) and lysis was calculated as percentage of dead cells or <inline-formula id="IEq2"><alternatives><tex-math id="d33e694">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\text{overall lysis }[\%]=\{1-(\text{cell count of condition})/(\text{cell count of condition w}/\text{o Ab})\}\times 100$$\end{document}</tex-math><mml:math id="d33e699"><mml:mrow><mml:mtext>overall lysis</mml:mtext><mml:mspace width="0.333333em"/><mml:mo stretchy="false">[</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>cell count of condition</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>cell count of condition w</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>o Ab</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">}</mml:mo><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="262_2025_4032_Article_IEq2.gif"/></alternatives></inline-formula>. NK-cell activation was evaluated by CD69 and CD107a expression.</p></sec><sec id="Sec6"><title>Antibody-dependent cellular phagocytosis (ADCP)</title><p id="Par49">Monocytes were isolated using the Classical Monocyte Isolation Kit (Miltenyi Biotec) and differentiated into macrophages in the presence of M-CSF (100&#x000a0;ng/ml; Biolegend) for 7&#x000a0;days.</p><p id="Par50">CellTrace Calcein Red&#x02013;Orange- or Far-Red-labeled macrophages were incubated with CellTrace CFSE-labelled target cells at an effector:target (E:T) ratio of 1:1 and a serial dilution of the antibodies (0.01&#x02013;10&#x000a0;nM) for 4&#x000a0;h. Analysis was performed using either the Amnis&#x000ae; Imagestream&#x000ae; MKII (Cytek Biosciences) or the Cytoflex LX (Beckman Coulter) flow cytometer. After doublet exclusion, the double-positive population represented the phagocytosed population.</p></sec><sec id="Sec7"><title>ADCC with primary EOC patient-derived organoids</title><p id="Par51">As previously described [<xref ref-type="bibr" rid="CR19">19</xref>], patient-derived organoids (PDOs) were derived from fresh tumor tissue by enzymatic digestion and isolation of progenitors, followed by differential seeding in Cultrex RGF Basement Membrane Extract, Type 2 (Bio-Techne), and growth media matrix to identify optimal patient-specific growth conditions.</p><p id="Par52">The assay was performed on a co-culture of freshly isolated NK cells (5:1 E:T ratio) and PDOs with the antibodies (50&#x000a0;nM) and IL-2 (10&#x000a0;nM) for 48&#x000a0;h. PDOs were retrieved from the 3D extracellular matrix by washing with ice-cold ADF F12 medium, supplemented with HEPES and Glutamax, and resuspended in growth medium. Technical replicates were digested with TrypLE to determine the number of single cells per PDO as approximately 2&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells per well. Phase contrast images were taken after 24 and 48&#x000a0;h. Cell viability was quantified by luminescence-based CellTiter-Glo 3D Assay (Promega), in independent quintuplicates per condition. Fluorescence images were obtained using a fully motorized Keyence BZ X-810 microscope, equipped with a Tokai stage-top incubator. Phenotypic characterization of the PDOs has been performed by immunofluorescence staining [<xref ref-type="bibr" rid="CR19">19</xref>] (Supplementary Table <xref rid="MOESM1" ref-type="media">S3</xref>).</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>EOC shows enriched MSLN expression and the highest CD47 mRNA expression across 30 cancer entities</title><p id="Par53">MSLN and CD47 are promising targets for immunotherapy [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. This was confirmed by a pan-cancer analysis of the TCGA cohort to evaluate the MSLN and CD47 mRNA expression levels across 30 cancer entities. MSLN mRNA was highly enriched in EOC and PDAC (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a) in contrast to healthy ovarian tissue (Supplementary Figure <xref rid="MOESM1" ref-type="media">S1</xref>a, b). MSLN protein expression was validated on primary EOC cells isolated from tumor tissue and ascites by MPFC (median MFI ratios 2.2 and 4.0, respectively; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b, Supplementary Figure <xref rid="MOESM1" ref-type="media">S1</xref>c, d). As expected, CD47 mRNA was highly abundant in all cancer entities evaluated and, interestingly, displayed the highest expression in EOC (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c, Supplementary Figure <xref rid="MOESM1" ref-type="media">S1</xref>a, b). Robust CD47 protein expression was validated in EOC cells by MPFC and is particularly prominent on tissue-derived cancer cells (median MFI ratio 41.8; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d, Supplementary Figure <xref rid="MOESM1" ref-type="media">S1</xref>c, d). Moreover, 73&#x02013;75% of EOC patients express CD47 and MSLN (Supplementary Figure <xref rid="MOESM1" ref-type="media">S1</xref>e). Analysis of the genomic alteration frequencies demonstrated the highest proportion of MSLN amplification in breast cancer and EOC (4%, and 2%, respectively; Supplementary Figure <xref rid="MOESM1" ref-type="media">S1</xref>f). Moreover, EOC displayed the highest CD47 amplification frequency at 6% (Supplementary Figure <xref rid="MOESM1" ref-type="media">S1</xref>g). These data further support MSLN and CD47 as promising targets for novel immunotherapeutic approaches in EOC.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>EOC features high MSLN and CD47 mRNA and protein levels. The mRNA expression of MSLN (<bold>a</bold>) and CD47 (<bold>c</bold>) was evaluated across 30 cancer entities using the TCGA-derived pan-cancer cohort (10,953 patients; 10,967 samples). The protein expression levels of MSLN (<bold>b</bold>) and CD47 (<bold>d</bold>) on primary EOC cells derived from EOC tissue (n&#x02009;=&#x02009;51) and ascites (n&#x02009;=&#x02009;34) are depicted as median fluorescence intensity (MFI) ratio in violin plots with median (gray line) and quartiles (dashed gray line). The black dashed line represents the threshold MFI ratio of 1.5. Statistical analysis was performed using an unpaired t-test, ***<italic>p</italic>&#x02009;&#x02264;&#x02009;0.001</p></caption><graphic xlink:href="262_2025_4032_Fig1_HTML" id="MO2"/></fig></p></sec><sec id="Sec10"><title>Generation and characterization of SIRP&#x003b1;-&#x003b1;MSLN LicMAb demonstrating MSLN-specificity and CD47-blocking capacity</title><p id="Par54">We generated anti-human MSLN mAbs using the hybridoma technique to identify two clones (4D8 and M4F5). The SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup> and SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup> LicMAbs were generated by fusing two <italic>N</italic>-terminal SIRP&#x003b1; immunoglobulin V-like domains to the V<sub>L</sub> chain of the antibody via a flexible (G<sub>4</sub>S)<sub>4</sub> linker (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). First, we investigated the impact of the <italic>N</italic>-terminal SIRP&#x003b1; fusion on the binding to MSLN by determining the K<sub>D</sub> value using surface plasmon resonance (SPR). The K<sub>D</sub>&#x000a0;values were in the low nanomolar range for all constructs, indicating the affinity for MSLN was unaffected by the fusion of the SIRP&#x003b1; domain (Supplementary Figure <xref rid="MOESM1" ref-type="media">S3</xref>a). Binding to CD47 occurred with lower affinity (K<sub>D</sub>&#x02009;=&#x02009;1&#x000a0;&#x000b5;M), consistent with previously measured affinities of SIRP&#x003b1; for CD47 [<xref ref-type="bibr" rid="CR20">20</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>The engineered SIRP&#x003b1;-&#x003b1;MSLN LicMAb is characterized by MSLN-specific targeting and CD47-blocking capacities. (<bold>a</bold>) A scheme of the SIRP&#x003b1;-&#x003b1;MSLN LicMAb targeting MSLN and simultaneously blocking CD47 on the cancer cells to switch on an &#x0201c;eat me&#x0201d; signal to the phagocytosing effector cells. The extracellular SIRP&#x003b1; domain that intrinsically has low affinity is fused to the IgG1 antibody light chains (V<sub>L</sub>) via a flexible (G<sub>4</sub>S)<sub>4</sub> linker. This scheme was created with BioRender (BioRender.com/g77u465). (<bold>b</bold>) A representative example of binding to OVCAR-3 (left) and SUIT-2-MSLN (right) cells by the indicated antibodies was evaluated by flow cytometry. (<bold>c</bold>) The binding to OVCAR-3 (left) and SUIT-2-MSLN cells (right) in a serial dilution of the indicated antibodies (0.0001&#x02013;100&#x000a0;nM) was evaluated by flow cytometry (n&#x02009;=&#x02009;3&#x02013;4). (<bold>d</bold>) The binding of the indicated antibodies to primary EOC cells derived from ascites was evaluated using flow cytometry (n&#x02009;=&#x02009;3). (<bold>e</bold>) The frequency of accessible CD47 on SUIT-2-MSLN cells was evaluated by flow cytometry using an APC-conjugated CD47-targeting antibody after incubation with the indicated antibodies (100&#x000a0;nM, n&#x02009;=&#x02009;4). Data represents the mean&#x02009;&#x000b1;&#x02009;SEM. Statistical analysis was performed using an ordinary one-way ANOVA, *<italic>p</italic>&#x02009;&#x02264;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x02264;&#x02009;0.01, and ****<italic>p</italic>&#x02009;&#x02264;&#x02009;0.0001</p></caption><graphic xlink:href="262_2025_4032_Fig2_HTML" id="MO3"/></fig></p><p id="Par55">We also analyzed binding to the MSLN-expressing EOC cell line OVCAR-3 and the MSLN-transduced PDAC cell line SUIT-2-MSLN by MPFC (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b,&#x000a0;c). The SIRP&#x003b1;&#x02013;&#x003b1;MSLN<sup>4D8</sup> LicMAb and the &#x003b1;CD47 mAb (h5F9-G4) mAb bound to OVCAR-3 cells similarly, with MFI ratios of 117.2 and 119.5, respectively. By contrast, the &#x003b1;MSLN<sup>4D8</sup> mAb showed a lower MFI ratio of 10.2, which can be explained by a 2.7-fold higher CD47 antigen density on the OVCAR-3 cell surface (Supplementary Figure <xref rid="MOESM1" ref-type="media">S2</xref>). As expected, the SIRP&#x003b1;&#x02013;&#x003b1;MSLN<sup>4D8</sup> LicMAb bound the SUIT-2-MSLN cells similarly to the &#x003b1;MSLN<sup>4D8</sup> and &#x003b1;CD47 mAb (h5F9-G4) mAb with MFI ratios of 27.5, 21.6, and 31.2, respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b,&#x000a0;c). Furthermore, primary EOC cells derived from ascites (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d) and tumor tissue (Supplementary Figure <xref rid="MOESM1" ref-type="media">S3</xref>b) were bound by the SIRP&#x003b1;&#x02013;&#x003b1;MSLN<sup>4D8</sup> LicMAb (MFI ratios 2.1 and 3.3, respectively), &#x003b1;MSLN<sup>4D8</sup> mAb (MFI ratios 2.2 and 3.3, respectively), and &#x003b1;CD47 mAb h5F9-G4 (MFI ratios 4.2 and 6.0, respectively). Importantly, the SIRP&#x003b1;&#x02013;&#x003b1;MSLN<sup>4D8</sup> LicMAb did not bind to MSLN<sup>neg</sup> patient-derived EOC cells (Supplementary Figure <xref rid="MOESM1" ref-type="media">S3</xref>c).</p><p id="Par56">One reason to generate LicMAbs is to retain the therapeutic benefit of blocking the CD47&#x02013;SIRP&#x003b1; interaction, specifically on tumor cells. To evaluate the CD47-blocking capacity, we analyzed the accessible CD47 on SUIT-2-MSLN cells by MPFC (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>e). In contrast to the high-affinity &#x003b1;CD47 mAbs h5F9-G4 and CC2C6, which blocked the majority of CD47 sites (6.2% and 2.3% accessible CD47, respectively), the SIRP&#x003b1;&#x02013;&#x003b1;MSLN<sup>4D8</sup> LicMAb was less efficacious in blocking CD47 (59.5% accessible CD47). To determine the specificity of MSLN targeting, we also evaluated the binding (Supplementary Figure <xref rid="MOESM1" ref-type="media">S3</xref>d) and blocking capacity (Supplementary Figure <xref rid="MOESM1" ref-type="media">S3</xref>e) of the SIRP&#x003b1;&#x02013;&#x003b1;MSLN<sup>4D8</sup> LicMAb to the MSLN<sup>neg</sup>/CD33<sup>pos</sup> AML cell line MOLM-13. The SIRP&#x003b1;&#x02013;&#x003b1;MSLN<sup>4D8</sup> LicMAb neither binds to MOLM-13 cells nor blocks CD47. By contrast, the isotype control SIRP&#x003b1;&#x02013;&#x003b1;CD33 LicMAb bound to CD33<sup>pos</sup>/CD47<sup>pos</sup> MOLM-13 cells and blocked CD47 (47% accessible CD47). These data show that the SIRP&#x003b1;&#x02013;&#x003b1;MSLN LicMAb binds to the MSLN-expressing EOC and PDAC cells while simultaneously blocking CD47.</p></sec><sec id="Sec11"><title>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb avoids on-target off-tumor binding</title><p id="Par57">We postulated that the SIRP&#x003b1;-&#x003b1;MSLN LicMAb specifically blocks CD47 on MSLN<sup>pos</sup> cancer cells. Consequently, the risk for potential adverse events by on-target off-tumor binding, such as anemia, neutropenia, and thrombocytopenia [<xref ref-type="bibr" rid="CR9">9</xref>], is reduced. To this end, we examined the SIRP&#x003b1;-&#x003b1;MSLN LicMAb binding to hematologic MSLN<sup>neg</sup>/CD47<sup>pos</sup> cells. In contrast to the high-affinity &#x003b1;CD47 (h5F9-G4) mAb, the SIRP&#x003b1;-&#x003b1;MSLN LicMAb did not bind to RBCs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, Supplementary Figure <xref rid="MOESM1" ref-type="media">S4</xref>b) or neutrophils (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b). Furthermore, unlike control molecules targeting CD47, the SIRP&#x003b1;-&#x003b1;MSLN LicMAb did not elicit platelet aggregation (Supplementary Figure <xref rid="MOESM1" ref-type="media">S4</xref>c). Interestingly, lymphocytes, which express CD47 at higher levels than RBCs and neutrophils (Supplementary Figure <xref rid="MOESM1" ref-type="media">S4</xref>a), were bound by the SIRP&#x003b1;-&#x003b1;MSLN LicMAb. However, compared to the high-affinity &#x003b1;CD47 (h5F9-G4) mAb with an EC<sub>50</sub> value of 0.26&#x000a0;nM, a fourfold lower MFI ratio was detected with a 40-fold higher EC<sub>50</sub> value of 12.0&#x000a0;nM. Unexpectedly, we found that the &#x003b1;MSLN mAb binds to lymphocytes at a high concentration of 100&#x000a0;nM. This result might explain the affinity of SIRP&#x003b1;-&#x003b1;MSLN LicMAb as an avidity effect of binding at MSLN and CD47. Further experiments are needed to precisely understand the mode of binding.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb avoids on-target off-tumor binding. The binding to red blood cells (RBCs, <bold>a</bold>), neutrophils (<bold>b</bold>), or lymphocytes (<bold>c</bold>) in a serial dilution (0.001&#x02013;100&#x000a0;nM) of the indicated antibodies was evaluated by flow cytometry (n&#x02009;=&#x02009;3&#x02013;6). In competitive binding assays, a 20-fold excess of CD47<sup>pos</sup> RBCs (d, gray bar) or tenfold excess of lymphocytes (e, gray bar) was co-cultured with OVCAR-3 (left) or SUIT-2-MSLN (right) target cells (black bars). Binding was evaluated by flow cytometry in the presence of antibodies (100&#x000a0;nM; n&#x02009;=&#x02009;5). Data represent the mean&#x02009;&#x000b1;&#x02009;SEM. Statistical analysis was performed using a 2way ANOVA and &#x00160;&#x000ed;d&#x000e1;k's multiple comparisons test. ns&#x02009;=&#x02009;not significant; ****<italic>p</italic>&#x02009;&#x02264;&#x02009;0.0001</p></caption><graphic xlink:href="262_2025_4032_Fig3_HTML" id="MO4"/></fig></p><p id="Par58">Next, we hypothesized that the SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup> LicMAb specifically binds to tumor cells in the presence of RBCs or lymphocytes. Even with a 20-fold excess of RBCs or tenfold excess of lymphocytes, the SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup> LicMAb was specifically bound to tumor cells. By contrast, the &#x003b1;CD47 mAb bound significantly more RBCs than tumor cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d) and did not discriminate between tumor cells and lymphocytes (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e).</p><p id="Par59">These data show that the SIRP&#x003b1;-&#x003b1;MSLN LicMAb binds specifically to MSLN-expressing tumor cells, a profile for potentially minimizing CD47-related on-target off-tumor toxicity.</p></sec><sec id="Sec12"><title>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb mediates ADCC against tumor cells</title><p id="Par60">Next, we investigated the potency of LicMAbs to induce NK-cell-mediated ADCC by noninvasive, real-time cellular impedance measurements (xCELLigence). Reproducible ADCC against OVCAR-3 cells was monitored as decreased impedance values (normalized cell index) over time (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). For comparability reasons, the area under curve (AUC) was calculated per condition and showed an E:&#x000a0;T-dependent decrease, particularly pronounced for the SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup> LicMAb. A high-affinity &#x003b1;CD47 IgG1 mAb (h5F9-G1) served as a positive control and gave the lowest and E:&#x000a0;T-independent AUC (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b). After 4&#x000a0;h in co-culture with NK cells, the OVCAR-3 cells had lysed in a dose-dependent manner. The SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup> and SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup> LicMAbs achieved 92% lysis (EC<sub>50</sub>&#x02009;=&#x02009;0.003&#x000a0;nM) and 100% lysis (EC<sub>50</sub>&#x02009;=&#x02009;0.003&#x000a0;nM), respectively, which was comparable to the &#x003b1;CD47 (h5F9-G1) mAb (96.4%). The &#x003b1;MSLN<sup>4D8</sup> and &#x003b1;MSLN<sup>M4F5</sup> showed lower maximum overall lysis (79.5% and 81.1%, respectively) and up to 70-fold higher EC<sub>50</sub> values, underlining the greater cytotoxic potency of the LicMAbs (0.216 and 0.019&#x000a0;nM, respectively; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb mediates dose-dependent and E:T ratio-dependent ADCC of tumor cells. (<bold>a</bold>) A representative example of NK-cell-mediated ADCC against OVCAR-3 cells in a 2:1 E:T ratio in the presence of the indicated antibodies (10&#x000a0;nM). ADCC was evaluated over time using the xCELLigence system. The cell indices were normalized to the timepoint of antibody and NK-cell addition. (<bold>b</bold>) The area under the curve (AUC) of the co-culture of OVCAR-3 cells and NK cells is shown for each antibody (10&#x000a0;nM) and the indicated E:T ratios. (<bold>c</bold>) The overall lysis after 4&#x000a0;h co-culture with serial dilutions of the indicated antibodies (0.1&#x000a0;pM&#x02013;10&#x000a0;nM) was calculated based on the background NK-cell-mediated cytotoxicity of OVCAR&#x02013;3 cells (5:1 E:T ratio; n&#x02009;=&#x02009;4&#x02013;5). The expression of CD69 (<bold>d</bold>) and CD107a (<bold>e</bold>) on the surface of NK cells after 4&#x000a0;h co-culture with OVCAR-3 cells (5:1 E:T ratio) is evaluated by flow cytometry (n&#x02009;=&#x02009;8 and n&#x02009;=&#x02009;6, respectively). Data represent the mean&#x02009;&#x000b1;&#x02009;SEM. Statistical analysis was performed using an ordinary one-way ANOVA; ***<italic>p</italic>&#x02009;&#x02264;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x02264;&#x02009;0.0001</p></caption><graphic xlink:href="262_2025_4032_Fig4_HTML" id="MO5"/></fig></p><p id="Par61">In parallel, we confirmed NK-cell-mediated lysis by MPFC (Supplementary Figure <xref rid="MOESM1" ref-type="media">S5</xref>). SIRP&#x003b1;-&#x003b1;MSLN LicMAbs induced comparable dose-dependent killing of OVCAR-3 and SUIT-2-MSLN cells. Due to high CD47 expression on OVCAR-3 cells, h5F9-G1 exhibited robust cytotoxicity of OVCAR-3 cells at lower concentrations. However, the SIRP&#x003b1;-&#x003b1;MSLN LicMAb achieved comparable maximum lysis (Supplementary Figure <xref rid="MOESM1" ref-type="media">S5</xref>a). In contrast, h5F9-G1 mediated decreased dose-dependent lysis of SUIT-2-MSLN cells based on a lower CD47 expression (Supplementary Figure <xref rid="MOESM1" ref-type="media">S5</xref>b). As expected, magrolimab did not induce cytotoxicity of SUIT-2-MSLN cells as the IgG4 scaffold minimizes Fc-dependent effector functions [<xref ref-type="bibr" rid="CR21">21</xref>]. Nevertheless, CD47<sup>high</sup> OVCAR-3 cells are lysed by magrolimab similarly to &#x003b1;MSLN mAbs (Supplementary Figure <xref rid="MOESM1" ref-type="media">S5</xref>a). In that regard, high levels of CD47 seem to support ADCC by targeting IgG4 molecules [<xref ref-type="bibr" rid="CR22">22</xref>]. The cytotoxicity data is further supported by a dose-dependent activation and degranulation of NK cells in co-culture with OVCAR-3 and SUIT-2-MSLN cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d,e; Supplementary Figure <xref rid="MOESM1" ref-type="media">S5</xref>c,d). Notably, the &#x003b1;MSLN<sup>4D8</sup> and &#x003b1;MSLN<sup>M4F5</sup> mAbs showed improved cytotoxicity as well as NK-cell activation and degranulation in comparison to the &#x003b1;MSLN IgG1 mAb amatuximab (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, Supplementary Figure <xref rid="MOESM1" ref-type="media">S5</xref>). These data demonstrate the robust capacity of the SIRP&#x003b1;-&#x003b1;MSLN LicMAb to kill solid tumor cell lines.</p></sec><sec id="Sec13"><title>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb is effective in the presence of soluble MSLN</title><p id="Par62">MSLN is anchored to the plasma membrane by a glycosyl-phosphatidylinositol linkage. However, shed MSLN can be found in sera from EOC and mesothelioma patients and, thus, represents a potential antigen sink to MSLN-targeting therapies [<xref ref-type="bibr" rid="CR23">23</xref>]. First, we measured the MSLN concentrations in the serum and ascites of EOC patient samples and in the supernatant of cultured ascites and patient-derived organoids (Supplementary Figure <xref rid="MOESM1" ref-type="media">S6</xref>a). We detected a median of 26.3&#x000a0;ng/ml soluble MSLN in the serum of EOC patients. Unexpectedly, reduced soluble MSLN was detected in fresh and cultured ascites of EOC patients and patient-derived organoids (median 5.4&#x000a0;ng/ml, 5.0&#x000a0;ng/ml, and 260&#x000a0;pg/ml, respectively). Next, we aimed to mimic shed MSLN using recombinant human MSLN (rhMSLN) and evaluate the functional capacity of the SIRP&#x003b1;-&#x003b1;MSLN LicMAb in its presence. To induce competition in vitro, we titrated rhMSLN to detect the saturated concentration, which inhibited MSLN binding. A concentration of 2.5&#x000a0;&#x000b5;M rhMSLN, at least 2000-fold higher than published data, completely abolished the binding of &#x003b1;MLSN<sup>M4F5</sup> mAb to SUIT-2-MSLN cells, whereas binding of the SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup> LicMAb was detected, albeit 40% reduced and with a 20-fold lower EC<sub>50</sub> value (Supplementary Figure <xref rid="MOESM1" ref-type="media">S6</xref>b,&#x000a0;c). Subsequently, we analyzed the impact of rhMSLN in functional assays. Most strikingly, and consistent with the LicMAb concept, the SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup> LicMAb was still effective in NK-cell-mediated killing of SUIT-2-MSLN cells in the presence of rhMSLN, albeit at higher concentrations (Supplementary Figure <xref rid="MOESM1" ref-type="media">S6</xref>d). The maximum lysis was reduced from 57.5% to 45.0% with rhMSLN, and the EC<sub>50</sub> values were increased from 0.007 to 0.239&#x000a0;nM. Importantly, rhMSLN almost completely abolished the cytotoxicity of the conventional &#x003b1;MLSN<sup>M4F5</sup> mAb. Taken together, our data support the hypothesis that soluble MSLN entirely affects the efficacy of standard &#x003b1;MLSN mAbs but not the multifunctional SIRP&#x003b1;-&#x003b1;MSLN LicMAb.</p></sec><sec id="Sec14"><title>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb mediates dose-dependent ADCP of tumor cells</title><p id="Par63">Next, we hypothesized that LicMAbs increase the phagocytic activity of macrophages due to the combination of CD47&#x02013;SIRP&#x003b1; blockade and an IgG1 pro-phagocytic stimulus. Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a shows the visualization of SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup>-induced phagocytosis of OVCAR-3 cells by imaging flow cytometry. Single cells were validated as brightfield (BF) images and successful phagocytosis as double-positive macrophages. Approximately one-third (31.8%) of OVCAR-3 cells were phagocytosed in the presence of the SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup> LicMAb, which is enhanced versus the &#x003b1;CD47 (25.4%) and &#x003b1;MSLN<sup>4D8</sup> (15.7%) mAbs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). The h5F9-G4 served as the positive control to address the maximum phagocytosis mediated by the CD47-SIRP&#x003b1; blockade. In parallel, traditional flow cytometry was used for high-throughput multi-parameter analysis of LicMAb-associated phagocytosis as a double-positive macrophage population (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>c). OVCAR-3 and SUIT-2-MSLN cells treated with SIRP&#x003b1;-&#x003b1;MSLN LicMAbs underwent comparable dose-dependent phagocytosis (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>d,&#x000a0;e; left). The SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup>-induced ADCP of MSLN<sup>low</sup>CD47<sup>high</sup> OVCAR-3 cells was significantly greater (92.5%) compared to the action of &#x003b1;CD47 mAb (72.7%) and particularly &#x003b1;MSLN<sup>4D8</sup> mAb (26.1%; Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>d, right). By contrast, the SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup> and &#x003b1;MSLN<sup>M4F5</sup> induced similar phagocytosis of MSLN-transduced SUIT-2-MSLN cells. Notably, magrolimab mediated only 27.1% ADCP (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>e, right). These data underline the enhanced phagocytic capacity of the SIRP&#x003b1;-&#x003b1;MSLN LicMAbs by blocking CD47.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb mediates dose-dependent ADCP of tumor cells. (<bold>a</bold>) Representative images of SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup>-mediated phagocytosis of CFSE<sup>pos</sup> OVCAR-3 cells by Cell Trace (CT) FarRed<sup>pos</sup> macrophages evaluated by imaging flow cytometry. Each row shows one representative example per donor. BF: brightfield. (<bold>b</bold>) The phagocytosed CFSE<sup>pos</sup>/CT FarRed<sup>pos</sup> OVCAR-3 population was quantified by imaging flow cytometry in the presence of the indicated antibodies (10&#x000a0;nM; n&#x02009;=&#x02009;3). (<bold>c</bold>) Representative FACS plots depict ADCP in the presence of the indicated antibodies (10&#x000a0;nM). The phagocytosed population is discriminated as CFSE<sup>pos</sup>/Calcein Red-Orange<sup>pos</sup> population (red rectangle). (<bold>d</bold>) The frequency of phagocytosed OVCAR-3 cells with serial dilutions of the indicated antibodies (left; 0.1&#x000a0;pM&#x02013;10&#x000a0;nM) and the normalized ADCP in the presence of antibodies (right; 10&#x000a0;nM) was evaluated by flow cytometry after 4&#x000a0;h co-culture (n&#x02009;=&#x02009;7). (<bold>e</bold>) The frequency of phagocytosed SUIT-2-MSLN cells with serial dilutions of the indicated antibodies (left; 0.1&#x000a0;pM&#x02013;10&#x000a0;nM) and the normalized ADCP in the presence of antibodies (right; 10&#x000a0;nM) was evaluated by flow cytometry after 4&#x000a0;h co-culture (n&#x02009;=&#x02009;4). Data represent the mean&#x02009;&#x000b1;&#x02009;SEM. Statistical analysis was performed using a one-way ANOVA; ****<italic>p</italic>&#x02009;&#x02264;&#x02009;0.0001</p></caption><graphic xlink:href="262_2025_4032_Fig5_HTML" id="MO6"/></fig></p></sec><sec id="Sec15"><title>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb is superior to a CD47xMSLN bispecific antibody</title><p id="Par64">Further, we compared the SIRP&#x003b1;-&#x003b1;MSLN LicMAb with a CD47xMSLN bispecific antibody (bsAb) similar to the published &#x003ba;&#x003bb; body from Hatterer et al. [<xref ref-type="bibr" rid="CR24">24</xref>]. First, we analyzed binding to SUIT-2-MSLN cells by MPFC (Supplementary Figure <xref rid="MOESM1" ref-type="media">S7</xref>a). The CD47xMSLN bsAb reached similar MFI ratios as the SIRP&#x003b1;&#x02013;&#x003b1;MSLN<sup>M4F5</sup> LicMAb (16.1 and 19.3, respectively), however, with an 18-fold higher EC<sub>50</sub> value, due to monovalent versus bivalent MLSN binding sites, respectively. Particularly, saturating concentrations of soluble MSLN as an alias for MSLN shedding reduced the binding of the CD47xMSLN bsAb by 87% in contrast to the SIRP&#x003b1;&#x02013;&#x003b1;MSLN<sup>M4F5</sup> LicMAb showing 53% reduced binding (MFI ratio 2.2 and 9.1, respectively). Next, we compared the NK-cell-mediated lysis of OVCAR-3 and SUIT-2-MSLN in a dose-dependent manner by MPFC (Supplementary Figure <xref rid="MOESM1" ref-type="media">S7</xref>b). In contrast to the CD47xMSLN bsAb, the SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup> LicMAb exhibited robust cytotoxicity of OVCAR-3 and SUIT-2-MSLN cells at low concentrations with a clear benefit in efficacy for the LicMAb as shown by an up to 900-fold reduced EC<sub>50</sub> value. The CD47xMSLN bsAb and SIRP&#x003b1;-&#x003b1;MSLN<sup>4D8</sup> LicMAb achieved similar maximum lysis of OVCAR-3 cells (39.6% and 38.1%, respectively) and SUIT-2-MSLN cells (33.7% and 46.9%, respectively). Moreover, we evaluated the phagocytic capacity of the antibody constructs (Supplementary Figure <xref rid="MOESM1" ref-type="media">S7</xref>c,&#x000a0;d). The CD47xMSLN bsAb induced lower dose-dependent phagocytosis of OVCAR-3 and SUIT-2-MSLN cells than the SIRP&#x003b1;-&#x003b1;MSLN LicMAbs. While the CD47xMSLN bsAb induced 51.0% and 59.3% ADCP of OVCAR-3 cells and SUIT-2-MSLN cells, respectively, the LicMAbs phagocytosed 85.2% and 92.0%, respectively. These data underline the superiority of the SIRP&#x003b1;-&#x003b1;MSLN LicMAbs to a CD47xMSLN bsAb.</p></sec><sec id="Sec16"><title>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb induces NK-cell-mediated cytotoxicity of EOC organoids</title><p id="Par65">To evaluate the SIRP&#x003b1;-&#x003b1;MSLN LicMAb in a model closer to the clinical context, we assessed its cytotoxic efficacy in primary EOC PDOs. The expression of MSLN (red) and epithelial cell adhesion molecule (EpCAM; green) was confirmed by immunofluorescence staining and flow cytometry (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a, Supplementary Figure <xref rid="MOESM1" ref-type="media">S8</xref>). Histochemistry revealed a more variable MSLN staining in the native tissue compared to an overall high MSLN expression in the respective organoid (Supplementary Figure <xref rid="MOESM1" ref-type="media">S8</xref>). Assessment of viability in a co-culture of PDOs and NK cells in a multi-well format ensured the technical robustness of the experimental setting. It demonstrated the high potential of SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup> to induce NK-cell-mediated organoid cell death (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b, c). A visual inspection of the interaction between NK cells and PDOs at 24&#x000a0;h revealed a characteristic pattern of cellular debris and decomposed fragments in SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup>-containing conditions (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b). The ability of the&#x000a0;SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup> LicMAb to activate NK cells and initiate organoid disintegration and cytotoxicity was also visualized by live-cell imaging (Supplemental video). Furthermore, after 48&#x000a0;h of SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup> LicMAb treatment, the total luminescence intensity was consistently lower than with magrolimab or &#x003b1;MSLN<sup>M4F5</sup>, confirming the largest decrease in living cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c). These data validate the cytotoxic capacity of the SIRP&#x003b1;-&#x003b1;MSLN LicMAb in a more clinically relevant model.<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>The SIRP&#x003b1;-&#x003b1;MSLN LicMAb enables NK-cell-mediated cytotoxic effects of EOC patient-derived organoids. (<bold>a)</bold> Representative immunofluorescence images of EOC patient-derived organoids (PDOs; biobank reference HGSO_6) expressing MSLN (red, left) and epithelial cell adhesion molecule (EpCAM, green, middle) and a merged image with DNA (blue, right). Scale bar: 50&#x000a0;&#x000b5;m. (<bold>b</bold>) Representative phase-contrast images of EOC PDOs (biobank reference HGSOC_35) after 24&#x000a0;h co-culture with NK cells (E:T ratio 5:1) and indicated antibodies (50&#x000a0;nM). Red arrows indicate cellular debris from organoids, as killing leads to the breakage of cell junctions and loss of epithelial architecture. The experiment is representative of 10 independent experiments with three different donor PDO lines showing the same pattern of SIRP&#x003b1;-&#x003b1;MSLN<sup>M4F5</sup> activity. Scale bars: 500&#x000a0;&#x000b5;m (<bold>c</bold>) Quantification of viable cells by Cell Titer glow depicting the total luminescence intensity after incubation of EOC PDOs with NK cells at an E:&#x000a0;T ratio of 5:1 and indicated antibodies (50&#x000a0;nM) after 48&#x000a0;h (n&#x02009;=&#x02009;3, biobank reference HGSOC_35, HGSO_20, HGSO_6). Data represent the mean&#x02009;&#x000b1;&#x02009;SEM.</p></caption><graphic xlink:href="262_2025_4032_Fig6_HTML" id="MO7"/></fig></p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par66">In this study, we prepared two preclinical LicMAb constructs (4D8 and M4F5) that induced an innate immune response restricted to MSLN-expressing solid cancers. Moreover, by cancer-directed CD47 blockade, we abolished CD47-related on-target off-tumor toxicities.</p><p id="Par67">CD47 was first reported as a promising target antigen in the context of hematologic malignancies. In this context, antibodies blocking CD47 indicated phagocytosis as a primary mode of action and showed robust antitumor efficacy [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. However, based on recent phase&#x000a0;III trial data on magrolimab in the context of AML, further development was deemed futile and terminated. Although we await full reports, the first preliminary data of the multi-center international trial revealed increased toxicity due to on-target off-leukemia effects [<xref ref-type="bibr" rid="CR25">25</xref>]. Furthermore, the combination with a hypomethylating agent to provide the pro-phagocytic signal [<xref ref-type="bibr" rid="CR25">25</xref>], necessary to enable high phagocytosis rates [<xref ref-type="bibr" rid="CR26">26</xref>], might not be the optimal approach. Other combinatorial approaches using mAbs as additional pro-phagocytic stimuli showed synergistic antitumor efficacy in hematologic [<xref ref-type="bibr" rid="CR15">15</xref>] and solid cancers [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Subsequently, bsAbs targeting a TAA and blocking the CD47&#x02013;SIRP&#x003b1; axis to dampen on-target off-tumor toxicities in solid tumors, were developed. Targeted TAAs include human epidermal growth factor receptor 2 (HER2) [<xref ref-type="bibr" rid="CR29">29</xref>], epidermal growth factor receptor (EGFR) [<xref ref-type="bibr" rid="CR30">30</xref>], and programmed death ligand 1 (PD-L1) [<xref ref-type="bibr" rid="CR31">31</xref>]. CD47xMSLN bsAbs have been generated as &#x003ba;&#x003bb; bodies with an &#x003b1;MSLN &#x003bb;-light chain and an &#x003b1;CD47 &#x003ba;-light chain [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], which are currently being investigated in a phase I clinical trial [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par68">We translated the concept of multifunctionality from hematologic [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] to solid tumors by fusing&#x000a0;the low-affinity SIRP&#x003b1; domains to an antibody targeting MSLN with high affinity. MSLN is a promising TAA as its expression levels are high on solid tumors, such as EOC and PDAC but limited on healthy cells. Furthermore, targeting MSLN prevents its interaction with cancer antigen CA-125, which has been implicated in supporting metastases [<xref ref-type="bibr" rid="CR18">18</xref>]. Hence, several MSLN-targeting strategies, such as mAbs [<xref ref-type="bibr" rid="CR35">35</xref>], antibody&#x02013;drug conjugates (ADCs) [<xref ref-type="bibr" rid="CR36">36</xref>], or chimeric antigen receptor T cell (CAR&#x000a0;T) cells, [<xref ref-type="bibr" rid="CR37">37</xref>] have been evaluated in clinical trials. Although amatuximab was well tolerated in MSLN<sup>pos</sup> tumor patients [<xref ref-type="bibr" rid="CR35">35</xref>], only its combination with chemotherapy gave beneficial results in mesothelioma patients [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par69">Notably, MSLN shedding is a mechanism by which high concentrations of MSLN accumulate in the serum of EOC and mesothelioma [<xref ref-type="bibr" rid="CR23">23</xref>]. Indeed, we detected soluble MSLN in the EOC patients&#x02019; serum, in line with the literature [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], and fivefold less in the ascites. Interestingly, Ok&#x00142;a et al. detected nearly tenfold greater levels of soluble MSLN in peritoneal fluid (622.8&#x000a0;pg/ml) versus plasma (81.6&#x000a0;pg/ml) of advanced EOC patients [<xref ref-type="bibr" rid="CR40">40</xref>]. However, these plasma concentrations are 300-fold lower than our data. To address the risk of shed MSLN acting as an antigen sink, we evaluated the binding and cytotoxicity of SIRP&#x003b1;-&#x003b1;MSLN LicMAb in the presence of soluble rhMSLN. As the clinically relevant concentrations are rather low and vary between patients and samples, a saturating concentration of rhMSLN was used to ensure challenging assay conditions in vitro. Although the functional capacity of an &#x003b1;MSLN mAb is highly reduced, the SIRP&#x003b1;-&#x003b1;MSLN LicMAb was still effective, albeit at higher concentrations. We suppose the avidity effects by binding MSLN and CD47 multivalently as the reason for maintaining the binding of the LicMAbs to target cells. Thus, bifunctional approaches such as using LicMAbs might maintain the therapeutic window even in the presence of shed MSLN and support MSLN and CD47 as promising targets to treat EOC. Furthermore, the clinical evaluation of CD47xMSLN &#x003ba;&#x003bb; bodies [<xref ref-type="bibr" rid="CR24">24</xref>] highlights the combined targeting of MSLN and CD47 as an encouraging strategy. Importantly, compared to the CD47xMSLN bsAb, SIRP&#x003b1;-&#x003b1;MSLN LicMAbs demonstrated enhanced binding, particularly in the presence of soluble MSLN, as well as increased cytotoxicity and phagocytosis.</p><p id="Par70">The antitumor efficacy of the SIRP&#x003b1;-&#x003b1;MSLN LicMAb is based on IgG1-induced NK-cell activation to effect ADCC and the simultaneous stimulation of phagocytic cells, such as macrophages, to mediate ADCP. Indeed, we confirm consistent cytotoxic and phagocytic activity against EOC and PDAC cell lines. Furthermore, we demonstrate the effective induction of cell death in organoids derived from EOC patients in co-culture with NK cells. Importantly, the SIRP&#x003b1;-&#x003b1;MSLN LicMAb induced more cytotoxicity and phagocytosis than the controls amatuximab and magrolimab. Using two different tumor cell lines emphasizes the reliable potency of the LicMAbs, independent of the antigen expression level. We hypothesize that these findings are transferrable to other MSLN-expressing solid tumor entities.</p><p id="Par71">Notably, MSLN was more uniformly expressed in patient-derived organoids than in respective native cancer tissue. As organoids are derived from the tumor&#x02019;s progenitor population, our data suggest that MSLN is associated with the stemness compartment driving tumor growth. Hence, the specific and enhanced killing activity against PDO cells of the LicMAb in comparison to magrolimab supports the interpretation that this multifunctional antibody may be advantageous to treat long-term tumor growth potential.</p><p id="Par72">Elevated expression levels of CD47 on healthy cells, notably RBCs, thrombocytes, and PBMCs, pose a concern for on-target off-tumor toxicity [<xref ref-type="bibr" rid="CR4">4</xref>]. Thus, phagocytic anemia was one of the most adverse events in patients receiving CD47-targeting agents, and neutropenia and thrombocytopenia were also frequently observed [<xref ref-type="bibr" rid="CR9">9</xref>]. Not surprisingly, highly CD47-expressing lymphocytes were targeted at high concentrations of the SIRP&#x003b1;-&#x003b1;MSLN LicMAb but less prominent than the high-affinity &#x003b1;CD47 mAb. Moreover, based on the unspecific binding of the &#x003b1;MSLN mAb at high concentrations, the LicMAb binding might rely on avidity effects by binding sites to MSLN and CD47. However, the SIRP&#x003b1;-&#x003b1;MSLN LicMAb did not bind to RBCs, the most abundant cells in the blood, nor to neutrophils. Most importantly, in competition, tumor cells were specifically targeted while binding to RBCs and lymphocytes was absent. In addition, reduced platelet aggregation lowers the risk of thrombocytopenia. This is in sharp contrast to a high-affinity &#x003b1;CD47 construct [<xref ref-type="bibr" rid="CR41">41</xref>] and underlines the potential of the LicMAb to minimize toxicity. Furthermore, a potential antigen sink effect is avoided because the low-affinity binding characteristics of the fused SIRP&#x003b1; domain prevent unspecific CD47 binding. This further enhances the efficacy of the SIRP&#x003b1;-&#x003b1;MSLN LicMAb therapeutic approach.</p><p id="Par73">CD47-targeting synergizes with the cytotoxicity of agents such as chemotherapies [<xref ref-type="bibr" rid="CR42">42</xref>], stimulator of interferon genes (STING) agonists [<xref ref-type="bibr" rid="CR43">43</xref>], and poly (ADP-ribose) polymerase inhibitors (PARPi) [<xref ref-type="bibr" rid="CR44">44</xref>] that are known to induce immunogenic cell death and thereby lead to upregulation of pro-phagocytic ligands [<xref ref-type="bibr" rid="CR44">44</xref>]. Thus, combinatorial approaches might increase the response rates of EOC and PDAC patients. Moreover, as adaptive ICIs such as &#x003b1;PD-1/ &#x003b1;PD&#x02013;L1 did not improve response rates in these patients [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], the combination with innate CD47 blockade using LicMAbs might synergize analogously with other cancer entities [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. It is known that CD47-targeting leads to an adaptive immune reaction by T cells [<xref ref-type="bibr" rid="CR47">47</xref>]. In that regard, the LicMAb might also induce cross-presentation to T cells by antigen-presenting cells, resulting in long-lasting anti-tumor effects. Future studies are awaited to validate this mechanism, which might lead to long-term tumor control. Furthermore, an inflammatory microenvironment with high IL-2 levels can activate NK cells and induce SIRP&#x003b1; upregulation as an inhibitory pathway [<xref ref-type="bibr" rid="CR48">48</xref>]. This additional mode of action could be targeted by the LicMAbs, further highlighting them as a promising concept.</p><p id="Par74">A limitation of our study is the focus on ex vivo data. Immunotherapy is beset by the lack of suitable immunocompetent animal models that allow human-specific binding domains to be tested. Hence, either humanized NSG mouse models injected with human cancer cell lines and effector cells serve as surrogates or murine antibody constructs would have been necessary. Each model system has limitations, and we opted for validation in the human organoid model, an advantageous research tool over mouse models regarding applicability and practicability, laboratory workload and costs, ethics, and high-throughput screening options [<xref ref-type="bibr" rid="CR49">49</xref>]. Accordingly, the efficient cytotoxic effects of primary EOC organoids validate the LicMAb in a more clinically relevant 3D model. However, humanized NSG mouse models with orthotopic cancer inoculation remain important for future studies to expand the preclinical evaluation and toxicity assessments of LicMAbs.</p><p id="Par75">In summary, our SIRP&#x003b1;-&#x003b1;MSLN LicMAb constructs show promising activity without on-target off-tumor toxicity in preclinical models. Hence, our data supports the further development of a SIRP&#x003b1;-&#x003b1;MSLN LicMAb for evaluation in early clinical trials on advanced ovarian and pancreatic cancer patients.</p></sec><sec id="Sec18" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="262_2025_4032_MOESM1_ESM.docx"><caption><p>Supplementary file 1 (DOCX 7544 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="262_2025_4032_MOESM2_ESM.avi"><caption><p>Supplementary file 2 (AVI 17 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="262_2025_4032_MOESM3_ESM.avi"><caption><p>Supplementary file 3 (AVI 8212 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="262_2025_4032_MOESM4_ESM.avi"><caption><p>Supplementary file 4 (AVI 180299 KB)</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>SIRP&#x003b1;</term><def><p id="Par4">Signal regulatory protein &#x003b1;</p></def></def-item><def-item><term>LicMAb</term><def><p id="Par5">Local inhibitory checkpoint monoclonal antibody</p></def></def-item><def-item><term>MSLN</term><def><p id="Par6">Mesothelin</p></def></def-item><def-item><term>EOC</term><def><p id="Par7">Epithelial ovarian cancer</p></def></def-item><def-item><term>PDAC</term><def><p id="Par8">Pancreatic ductal adenocarcinoma</p></def></def-item><def-item><term>ADCC</term><def><p id="Par9">Antibody-dependent cellular cytotoxicity</p></def></def-item><def-item><term>ADCP</term><def><p id="Par10">Antibody-dependent cellular phagocytosis</p></def></def-item><def-item><term>FcR</term><def><p id="Par11">Fc receptor</p></def></def-item><def-item><term>GrzB</term><def><p id="Par12">Granzyme B</p></def></def-item><def-item><term>M&#x000d8;</term><def><p id="Par13">Macrophages</p></def></def-item><def-item><term>mAbs</term><def><p id="Par14">Monoclonal antibodies</p></def></def-item><def-item><term>ICIs</term><def><p id="Par15">Immune checkpoint inhibitors</p></def></def-item><def-item><term>RBCs</term><def><p id="Par16">Red blood cells</p></def></def-item><def-item><term>TAA</term><def><p id="Par17">Tumor-associated antigen</p></def></def-item><def-item><term>V<sub>L</sub></term><def><p id="Par18">Variable light chain</p></def></def-item><def-item><term>V<sub>H</sub></term><def><p id="Par19">Variable heavy chain</p></def></def-item><def-item><term>(G<sub>4</sub>S)<sub>4</sub></term><def><p id="Par20">Polyglycine-serine linker of 4 repeats</p></def></def-item><def-item><term>E</term><def><p id="Par21">T ratio: Effector: target ratio</p></def></def-item><def-item><term>PDOs</term><def><p id="Par22">Patient-derived organoids</p></def></def-item><def-item><term>MPFC</term><def><p id="Par23">Multiparametric flow cytometry</p></def></def-item><def-item><term>MFI</term><def><p id="Par24">Median fluorescence intensity</p></def></def-item><def-item><term>SPR</term><def><p id="Par25">Surface plasmon resonance</p></def></def-item><def-item><term>AUC</term><def><p id="Par26">Area under curve</p></def></def-item><def-item><term>rhMSLN</term><def><p id="Par27">Recombinant human MSLN</p></def></def-item><def-item><term>BF</term><def><p id="Par28">Brightfield</p></def></def-item><def-item><term>CT</term><def><p id="Par29">Cell Trace&#x02122;</p></def></def-item><def-item><term>EpCAM</term><def><p id="Par30">Epithelial cell adhesion molecule</p></def></def-item><def-item><term>bsAb</term><def><p id="Par31">Bispecific antibody</p></def></def-item><def-item><term>HER2</term><def><p id="Par32">Human epidermal growth factor receptor 2</p></def></def-item><def-item><term>EGFR</term><def><p id="Par33">Epidermal growth factor receptor</p></def></def-item><def-item><term>GPC3</term><def><p id="Par34">Glypican-3</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par35">Programmed death ligand 1</p></def></def-item><def-item><term>ADC</term><def><p id="Par36">Antibody&#x02013;drug conjugate</p></def></def-item><def-item><term>CART</term><def><p id="Par37">Chimeric antigen receptor T cell</p></def></def-item><def-item><term>PARPi</term><def><p id="Par38">Poly ADP ribose polymerase inhibitors</p></def></def-item><def-item><term>STING</term><def><p id="Par39">Stimulator of interferon genes</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Anna Reischer, Alexandra Leutbecher, Nadja C. Fenn and Marion Subklewe: Contributed equally.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Sabine Sandner-Thiede and Simone Pentz (University Hospital, LMU Munich) for their excellent technical support and the study nurses, Bettina Ganseder and Natalie Kronthaler (University Hospital Munich), for their assistance in patient recruitment and sample collection. We acknowledge Maria Fischer for her assistance in the live-cell imaging of the EOC organoid-killing assay and Martina Rahmeh for the immunohistochemistry stainings. We acknowledge Elisabeth Kremmer for supporting the MSLN generation. We thank Prof. Dr. Sebastian Kobold for generously providing the SUIT-2-MSLN cell line used in this study. The graphical abstract and Figure 2a were created with BioRender (Neumann, A. (2023) BioRender.com/g77u465). This work was supported by the BMBF in the framework of the Cluster4Future program (Cluster for Nucleic Acid Therapeutics Munich, CNATM) (Project ID: (03ZU1201AA). We thank our thrombocyte apheresis collection center in the division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, LMU Munich, for providing us with the leukoreduced single-donor platelet concentrate chambers. We acknowledge the iFlow Core Facility of the University Hospital, LMU Munich (INST 409/225-1 FUGG) for assistance in generating flow cytometry data and the Core Facility Flow Cytometry at the Biomedical Center, LMU Munich, for providing equipment, services, and expertise.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>A.L., N.F., A.R., M.S.: manuscript writing and editing. A.L., B.H., E.P., K.W., N.C.F., M.K., A.R.: experiment performance and data acquisition and analysis. A.L., B.H., E.P., K.W., N.C.F., M.K., A.R., B.T., A.H.C., A.S., L.R., L.Wi., L.Wy. B.C., F.T., S.M.: involved in research design and data interpretation. N.C.F., M.S., K-P.H.: study design and supervision. H.F., H.L. involved in MSLN antibody generation. C.W., D.M. provided the leukoreduction chamber material. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL. The work was supported by the Bavarian Elite Graduate School "i-target" (A.L., A.H-C., L.R.), the Else-Kr&#x000f6;ner-Fresenius Forschungskolleg CSP Cancer Immunotherapy (A.R.), the Sonderforschungsbereich SFB&#x000a0;338 (M.S.), Deutsche Forschungsgemeinschaft (DFG) 451580403 (M.S., K-P.H.), 452881907 (M.S.) and Exist Transfer of Research I grant (N.F.).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets analyzed during the current study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par76">PB samples from HDs or leukoreduction system chambers (LRSC) from plate-apheresis were collected with written consent following the Declaration of Helsinki and with approval from the Institutional Review Board of LMU Munich (23&#x02013;0283). The collection of ovarian cancer tissue for biobanking and generation of organoids has been approved by the Ethics Commission of LMU University (17&#x02013;0471), and written consent of each patient has been obtained.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par77">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par78">K-P.H., M.S., and N.C.F. are inventors of a patent application regarding the SIRP&#x003b1;&#x02011;antibody fusion proteins. M.S. has received industry research support from Amgen, Gilead, Miltenyi Biotec, Morphosys, Roche, and Seattle Genetics, and has served as a consultant/advisor to Amgen, BMS, Celgene, Gilead, Pfizer, Novartis, and Roche. She sits on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics, and serves on the speakers' bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer. F.T.: grants and personal fees from AbbVie, AstraZeneca, Eisai, GSK, ImmunoGen, MSD, Roche, and SAGA diagnostics S.M.: Research funding, advisory board, honorary or travel expenses: AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Hubro, Immunogen, Medac, MSD, Novartis, Nykode, Olympus, PharmaMar, Pfizer, Roche, Seagen, Sensor Kinesis, Teva. M.K.: inventor of the European Patent for ovarian cancer organoid culture. B.C.: Honoraria from AstraZeneca. A.L., A.R., B.H., E.P., K.W., B.T., A.H-C.; A.S., L.R., L.Wi., L.Wy., C.W., D.M., declare no relevant conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Luke</surname><given-names>JJ</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name></person-group><article-title>Targeted agents and immunotherapies: optimizing outcomes in melanoma</article-title><source>Nat Rev Clin Oncol</source><year>2017</year><volume>14</volume><fpage>463</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2017.43</pub-id><pub-id pub-id-type="pmid">28374786</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14:463&#x02013;482. 10.1038/nrclinonc.2017.43<pub-id pub-id-type="pmid">28374786</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Balsano</surname><given-names>R</given-names></name><name><surname>Zanuso</surname><given-names>V</given-names></name><name><surname>Pirozzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pancreatic ductal adenocarcinoma and immune checkpoint inhibitors: the gray curtain of immunotherapy and spikes of lights</article-title><source>Curr Oncol</source><year>2023</year><volume>30</volume><fpage>3871</fpage><lpage>3885</lpage><pub-id pub-id-type="doi">10.3390/curroncol30040293</pub-id><pub-id pub-id-type="pmid">37185406</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Balsano R, Zanuso V, Pirozzi A et al (2023) Pancreatic ductal adenocarcinoma and immune checkpoint inhibitors: the gray curtain of immunotherapy and spikes of lights. Curr Oncol 30:3871&#x02013;3885. 10.3390/curroncol30040293<pub-id pub-id-type="pmid">37185406</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis</article-title><source>Front Pharmacol</source><year>2023</year><volume>14</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3389/fphar.2023.1111061</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zeng S, Liu D, Yu Y et al (2023) Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis. Front Pharmacol 14:1&#x02013;10. 10.3389/fphar.2023.1111061</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Oldenborg</surname><given-names>PA</given-names></name><name><surname>Zheleznyak</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>YF</given-names></name><etal/></person-group><article-title>Role of CD47 as a marker of self on red blood cells</article-title><source>Science (80-)</source><year>2000</year><volume>288</volume><fpage>2051</fpage><lpage>2054</lpage><pub-id pub-id-type="doi">10.1126/science.288.5473.2051</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Oldenborg PA, Zheleznyak A, Fang YF et al (2000) Role of CD47 as a marker of self on red blood cells. Science (80-) 288:2051&#x02013;2054. 10.1126/science.288.5473.2051</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Willingham</surname><given-names>SB</given-names></name><name><surname>Volkmer</surname><given-names>J-P</given-names></name><name><surname>Gentles</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors</article-title><source>Proc Natl Acad Sci</source><year>2012</year><volume>109</volume><fpage>6662</fpage><lpage>6667</lpage><pub-id pub-id-type="doi">10.1073/pnas.1121623109</pub-id><pub-id pub-id-type="pmid">22451913</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Willingham SB, Volkmer J-P, Gentles AJ et al (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci 109:6662&#x02013;6667. 10.1073/pnas.1121623109<pub-id pub-id-type="pmid">22451913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>S</given-names></name><name><surname>Jamieson</surname><given-names>CHM</given-names></name><name><surname>Pang</surname><given-names>WW</given-names></name><etal/></person-group><article-title>CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis</article-title><source>Cell</source><year>2009</year><volume>138</volume><fpage>271</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.05.046</pub-id><pub-id pub-id-type="pmid">19632178</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Jaiswal S, Jamieson CHM, Pang WW et al (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271&#x02013;285. 10.1016/j.cell.2009.05.046<pub-id pub-id-type="pmid">19632178</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>MP</given-names></name><name><surname>Takimoto</surname><given-names>CH</given-names></name><name><surname>Feng</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies</article-title><source>Front Oncol</source><year>2019</year><volume>9</volume><fpage>1380</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.01380</pub-id><pub-id pub-id-type="pmid">32038992</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Chao MP, Takimoto CH, Feng DD et al (2019) Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol 9:1380. 10.3389/fonc.2019.01380<pub-id pub-id-type="pmid">32038992</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Sikic</surname><given-names>BI</given-names></name><name><surname>Lakhani</surname><given-names>N</given-names></name><name><surname>Patnaik</surname><given-names>A</given-names></name><etal/></person-group><article-title>First-in-human, first-in-class Phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><fpage>946</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.02018</pub-id><pub-id pub-id-type="pmid">30811285</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Sikic BI, Lakhani N, Patnaik A et al (2019) First-in-human, first-in-class Phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol 37:946&#x02013;953. 10.1200/JCO.18.02018<pub-id pub-id-type="pmid">30811285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Sallman</surname><given-names>DA</given-names></name><name><surname>Al Malki</surname><given-names>MM</given-names></name><name><surname>Asch</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Magrolimab in combination with Azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a Phase Ib study</article-title><source>J Clin Oncol Off J Am Soc Clin Oncol</source><year>2023</year><volume>41</volume><fpage>2815</fpage><lpage>2826</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01794</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Sallman DA, Al Malki MM, Asch AS et al (2023) Magrolimab in combination with Azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a Phase Ib study. J Clin Oncol Off J Am Soc Clin Oncol 41:2815&#x02013;2826. 10.1200/JCO.22.01794</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Burris</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Spira</surname><given-names>AI</given-names></name><name><surname>Taylor</surname><given-names>MH</given-names></name><etal/></person-group><article-title>A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors</article-title><source>J Clin Oncol</source><year>2021</year><volume>39</volume><fpage>2516</fpage><pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.2516</pub-id><pub-id pub-id-type="pmid">34101483</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Burris HA III, Spira AI, Taylor MH et al (2021) A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors. J Clin Oncol 39:2516. 10.1200/JCO.2021.39.15_suppl.2516<pub-id pub-id-type="pmid">34101483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Daver NG, Stevens DA, Hou J-Z et al (2022) Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): a phase 1b dose escalation study. J Clin Oncol 40:TPS7067&#x02013;TPS7067. 10.1200/JCO.2022.40.16_suppl.TPS7067</mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>S-Q</given-names></name><name><surname>Du</surname><given-names>Y-X</given-names></name><etal/></person-group><article-title>Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile</article-title><source>J Transl Med</source><year>2024</year><volume>22</volume><fpage>220</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04710-6</pub-id><pub-id pub-id-type="pmid">38429732</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Wang T, Wang S-Q, Du Y-X et al (2024) Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile. J Transl Med 22:220. 10.1186/s12967-023-04710-6<pub-id pub-id-type="pmid">38429732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Ansell</surname><given-names>SM</given-names></name><name><surname>Maris</surname><given-names>MB</given-names></name><name><surname>Lesokhin</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies</article-title><source>Clin Cancer Res Off J Am Assoc Cancer Res</source><year>2021</year><volume>27</volume><fpage>2190</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-3706</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ansell SM, Maris MB, Lesokhin AM et al (2021) Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res Off J Am Assoc Cancer Res 27:2190&#x02013;2199. 10.1158/1078-0432.CCR-20-3706</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Lakhani</surname><given-names>NJ</given-names></name><name><surname>Chow</surname><given-names>LQM</given-names></name><name><surname>Gainor</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><fpage>1740</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00584-2</pub-id><pub-id pub-id-type="pmid">34793719</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Lakhani NJ, Chow LQM, Gainor JF et al (2021) Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol 22:1740&#x02013;1751. 10.1016/S1470-2045(21)00584-2<pub-id pub-id-type="pmid">34793719</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Advani</surname><given-names>R</given-names></name><name><surname>Flinn</surname><given-names>I</given-names></name><name><surname>Popplewell</surname><given-names>L</given-names></name><etal/></person-group><article-title>CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin&#x02019;s lymphoma</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><fpage>1711</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1807315</pub-id><pub-id pub-id-type="pmid">30380386</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Advani R, Flinn I, Popplewell L et al (2018) CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin&#x02019;s lymphoma. N Engl J Med 379:1711&#x02013;1721. 10.1056/NEJMoa1807315<pub-id pub-id-type="pmid">30380386</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Ponce</surname><given-names>LP</given-names></name><name><surname>Fenn</surname><given-names>NC</given-names></name><name><surname>Moritz</surname><given-names>N</given-names></name><etal/></person-group><article-title>SIRP&#x003b1;-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>11284</fpage><lpage>11301</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14500</pub-id><pub-id pub-id-type="pmid">28061465</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ponce LP, Fenn NC, Moritz N et al (2017) SIRP&#x003b1;-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Oncotarget 8:11284&#x02013;11301. 10.18632/oncotarget.14500<pub-id pub-id-type="pmid">28061465</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Tahk</surname><given-names>S</given-names></name><name><surname>Vick</surname><given-names>B</given-names></name><name><surname>Hiller</surname><given-names>B</given-names></name><etal/></person-group><article-title>SIRP&#x003b1;-&#x003b1;CD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells</article-title><source>J Hematol Oncol</source><year>2021</year><volume>14</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1186/s13045-021-01163-6</pub-id><pub-id pub-id-type="pmid">33402199</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Tahk S, Vick B, Hiller B et al (2021) SIRP&#x003b1;-&#x003b1;CD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells. J Hematol Oncol 14:1&#x02013;17. 10.1186/s13045-021-01163-6<pub-id pub-id-type="pmid">33402199</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Weidemann</surname><given-names>S</given-names></name><name><surname>Gagelmann</surname><given-names>P</given-names></name><name><surname>Gorbokon</surname><given-names>N</given-names></name><etal/></person-group><article-title>Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors</article-title><source>Biomedicines</source><year>2021</year><pub-id pub-id-type="doi">10.3390/biomedicines9040397</pub-id><pub-id pub-id-type="pmid">34944647</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Weidemann S, Gagelmann P, Gorbokon N et al (2021) Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors. Biomedicines. 10.3390/biomedicines9040397<pub-id pub-id-type="pmid">34944647</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Trillsch</surname><given-names>F</given-names></name><name><surname>Czogalla</surname><given-names>B</given-names></name><name><surname>Kraus</surname><given-names>F</given-names></name><etal/></person-group><article-title>Protocol to optimize the biobanking of ovarian cancer organoids by accommodating patient-specific differences in stemness potential</article-title><source>STAR Protoc</source><year>2023</year><volume>4</volume><fpage>102484</fpage><pub-id pub-id-type="doi">10.1016/j.xpro.2023.102484</pub-id><pub-id pub-id-type="pmid">37585293</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Trillsch F, Czogalla B, Kraus F et al (2023) Protocol to optimize the biobanking of ovarian cancer organoids by accommodating patient-specific differences in stemness potential. STAR Protoc 4:102484. 10.1016/j.xpro.2023.102484<pub-id pub-id-type="pmid">37585293</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>K</given-names></name><name><surname>Ring</surname><given-names>AM</given-names></name><name><surname>Ho</surname><given-names>CCM</given-names></name><etal/></person-group><article-title>Engineered SIRP&#x003b1; variants as immunotherapeutic adjuvants to anticancer antibodies</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1126/science.1238856</pub-id><pub-id pub-id-type="pmid">23722425</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Weiskopf K, Ring AM, Ho CCM et al (2013) Engineered SIRP&#x003b1; variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341:88&#x02013;91. 10.1126/science.1238856<pub-id pub-id-type="pmid">23722425</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><etal/></person-group><article-title>Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>137345</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0137345</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Liu J, Wang L, Zhao F et al (2015) Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE 10:137345. 10.1371/journal.pone.0137345</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Steplewski</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>LK</given-names></name><name><surname>Shearman</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity</article-title><source>Proc Natl Acad Sci USA</source><year>1988</year><volume>85</volume><fpage>4852</fpage><lpage>4856</lpage><pub-id pub-id-type="doi">10.1073/pnas.85.13.4852</pub-id><pub-id pub-id-type="pmid">3387441</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Steplewski Z, Sun LK, Shearman CW et al (1988) Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85:4852&#x02013;4856. 10.1073/pnas.85.13.4852<pub-id pub-id-type="pmid">3387441</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>R</given-names></name><name><surname>Remaley</surname><given-names>AT</given-names></name><name><surname>Sampson</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>447</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1477</pub-id><pub-id pub-id-type="pmid">16428485</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Hassan R, Remaley AT, Sampson ML et al (2006) Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12:447&#x02013;453. 10.1158/1078-0432.CCR-05-1477<pub-id pub-id-type="pmid">16428485</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>E</given-names></name><name><surname>Medioni</surname><given-names>J</given-names></name><name><surname>Rouge</surname><given-names>TDLM</given-names></name><etal/></person-group><article-title>A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><fpage>A740 LP</fpage><pub-id pub-id-type="doi">10.1136/jitc-2022-SITC2022.0707</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Romano E, Medioni J, Rouge TDLM et al (2022) A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers. J Immunother Cancer 10:A740 LP. 10.1136/jitc-2022-SITC2022.0707</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Naval</surname><given-names>D</given-names></name><name><surname>Paresh</surname><given-names>V</given-names></name><name><surname>Gerwin</surname><given-names>H</given-names></name><etal/></person-group><article-title>Magrolimab vs placebo in combination with Venetoclax and Azacitidine in previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: the ENHANCE-3 study</article-title><source>EHA Libr</source><year>2024</year><volume>422242</volume><fpage>138</fpage></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Naval D, Paresh V, Gerwin H et al (2024) Magrolimab vs placebo in combination with Venetoclax and Azacitidine in previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: the ENHANCE-3 study. EHA Libr 422242:138</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Osorio</surname><given-names>JC</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Knorr</surname><given-names>DA</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name></person-group><article-title>The antitumor activities of anti-CD47 antibodies require Fc-Fc&#x003b3;R interactions</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>2051</fpage><lpage>2065.e6</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.10.007</pub-id><pub-id pub-id-type="pmid">37977147</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Osorio JC, Smith P, Knorr DA, Ravetch JV (2023) The antitumor activities of anti-CD47 antibodies require Fc-Fc&#x003b3;R interactions. Cancer Cell 41:2051-2065.e6. 10.1016/j.ccell.2023.10.007<pub-id pub-id-type="pmid">37977147</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Theruvath</surname><given-names>J</given-names></name><name><surname>Menard</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>BAH</given-names></name><etal/></person-group><article-title>Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01625-x</pub-id><pub-id pub-id-type="pmid">35027753</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Theruvath J, Menard M, Smith BAH et al (2022) Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med 28:333&#x02013;344. 10.1038/s41591-021-01625-x<pub-id pub-id-type="pmid">35027753</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses</article-title><source>MAbs</source><year>2018</year><volume>10</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1080/19420862.2017.1409319</pub-id><pub-id pub-id-type="pmid">29182441</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Liu B, Guo H, Xu J et al (2018) Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. MAbs 10:315&#x02013;324. 10.1080/19420862.2017.1409319<pub-id pub-id-type="pmid">29182441</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><etal/></person-group><article-title>Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy</article-title><source>Drug Resist Updat</source><year>2024</year><volume>74</volume><fpage>101068</fpage><pub-id pub-id-type="doi">10.1016/j.drup.2024.101068</pub-id><pub-id pub-id-type="pmid">38402670</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhang B, Shi J, Shi X et al (2024) Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resist Updat 74:101068. 10.1016/j.drup.2024.101068<pub-id pub-id-type="pmid">38402670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>MAJM</given-names></name><name><surname>Ploeg</surname><given-names>EM</given-names></name><name><surname>Koopmans</surname><given-names>I</given-names></name><etal/></person-group><article-title>Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRP&#x003b1; &#x0201c;don&#x02019;t eat me&#x0201d; immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation</article-title><source>Oncoimmunology</source><year>2020</year><pub-id pub-id-type="doi">10.1080/2162402X.2020.1824323</pub-id><pub-id pub-id-type="pmid">33299654</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Hendriks MAJM, Ploeg EM, Koopmans I et al (2020) Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRP&#x003b1; &#x0201c;don&#x02019;t eat me&#x0201d; immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. Oncoimmunology. 10.1080/2162402X.2020.1824323<pub-id pub-id-type="pmid">33299654</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity</article-title><source>Cancer Immunol Immunother</source><year>2021</year><volume>70</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02679-5</pub-id><pub-id pub-id-type="pmid">32761423</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wang Y, Ni H, Zhou S et al (2021) Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunol Immunother 70:365&#x02013;376. 10.1007/s00262-020-02679-5<pub-id pub-id-type="pmid">32761423</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Hatterer</surname><given-names>E</given-names></name><name><surname>Chauchet</surname><given-names>X</given-names></name><name><surname>Richard</surname><given-names>F</given-names></name><etal/></person-group><article-title>Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors</article-title><source>MAbs</source><year>2020</year><pub-id pub-id-type="doi">10.1080/19420862.2020.1739408</pub-id><pub-id pub-id-type="pmid">32191151</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Hatterer E, Chauchet X, Richard F et al (2020) Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. MAbs. 10.1080/19420862.2020.1739408<pub-id pub-id-type="pmid">32191151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Dheilly</surname><given-names>E</given-names></name><name><surname>Moine</surname><given-names>V</given-names></name><name><surname>Broyer</surname><given-names>L</given-names></name><etal/></person-group><article-title>Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies</article-title><source>Mol Ther</source><year>2017</year><volume>25</volume><fpage>523</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2016.11.006</pub-id><pub-id pub-id-type="pmid">28153099</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Dheilly E, Moine V, Broyer L et al (2017) Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther 25:523&#x02013;533. 10.1016/j.ymthe.2016.11.006<pub-id pub-id-type="pmid">28153099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Piccione</surname><given-names>EC</given-names></name><name><surname>Juarez</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells</article-title><source>MAbs</source><year>2015</year><volume>7</volume><fpage>946</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1080/19420862.2015.1062192</pub-id><pub-id pub-id-type="pmid">26083076</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Piccione EC, Juarez S, Liu J et al (2015) A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 7:946&#x02013;956. 10.1080/19420862.2015.1062192<pub-id pub-id-type="pmid">26083076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Fujisaka</surname><given-names>Y</given-names></name><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><etal/></person-group><article-title>Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors</article-title><source>Invest New Drugs</source><year>2015</year><volume>33</volume><fpage>380</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1007/s10637-014-0196-0</pub-id><pub-id pub-id-type="pmid">25502863</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Fujisaka Y, Kurata T, Tanaka K et al (2015) Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs 33:380&#x02013;388. 10.1007/s10637-014-0196-0<pub-id pub-id-type="pmid">25502863</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Santin</surname><given-names>AD</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Gonz&#x000e1;lez-Mart&#x000ed;n</surname><given-names>A</given-names></name><etal/></person-group><article-title>Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study</article-title><source>Int J Gynecol Cancer</source><year>2023</year><volume>33</volume><fpage>562</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1136/ijgc-2022-003927</pub-id><pub-id pub-id-type="pmid">36564099</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Santin AD, Vergote I, Gonz&#x000e1;lez-Mart&#x000ed;n A et al (2023) Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. Int J Gynecol Cancer 33:562&#x02013;570<pub-id pub-id-type="pmid">36564099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>R</given-names></name><name><surname>Butler</surname><given-names>M</given-names></name><name><surname>O&#x02019;Cearbhaill</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results</article-title><source>Nat Med</source><year>2023</year><volume>29</volume><fpage>2099</fpage><lpage>2109</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02452-y</pub-id><pub-id pub-id-type="pmid">37501016</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Hassan R, Butler M, O&#x02019;Cearbhaill RE et al (2023) Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. Nat Med 29:2099&#x02013;2109. 10.1038/s41591-023-02452-y<pub-id pub-id-type="pmid">37501016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>R</given-names></name><name><surname>Kindler</surname><given-names>HL</given-names></name><name><surname>Jahan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>5927</fpage><lpage>5936</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0804</pub-id><pub-id pub-id-type="pmid">25231400</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Hassan R, Kindler HL, Jahan T et al (2014) Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res 20:5927&#x02013;5936. 10.1158/1078-0432.CCR-14-0804<pub-id pub-id-type="pmid">25231400</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Cheng</surname><given-names>WF</given-names></name><name><surname>Lee</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Serum mesothelin in epithelial ovarian carcinoma: A new screening marker and prognostic factor</article-title><source>Anticancer Res</source><year>2006</year><volume>26</volume><fpage>4721</fpage><lpage>4728</lpage><pub-id pub-id-type="pmid">17214332</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Huang CY, Cheng WF, Lee CN et al (2006) Serum mesothelin in epithelial ovarian carcinoma: A new screening marker and prognostic factor. Anticancer Res 26:4721&#x02013;4728<pub-id pub-id-type="pmid">17214332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Ok&#x00142;a</surname><given-names>K</given-names></name><name><surname>Sur&#x000f3;wka</surname><given-names>J</given-names></name><name><surname>Fr&#x00105;szczak</surname><given-names>K</given-names></name><etal/></person-group><article-title>Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients</article-title><source>Tumor Biol</source><year>2018</year><volume>40</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1177/1010428318804937</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Ok&#x00142;a K, Sur&#x000f3;wka J, Fr&#x00105;szczak K et al (2018) Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients. Tumor Biol 40:1&#x02013;15. 10.1177/1010428318804937</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Velliquette</surname><given-names>RW</given-names></name><name><surname>Aeschlimann</surname><given-names>J</given-names></name><name><surname>Kirkegaard</surname><given-names>J</given-names></name><etal/></person-group><article-title>Monoclonal anti-CD47 interference in red cell and platelet testing</article-title><source>Transfusion</source><year>2019</year><volume>59</volume><fpage>730</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1111/trf.15033</pub-id><pub-id pub-id-type="pmid">30516833</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Velliquette RW, Aeschlimann J, Kirkegaard J et al (2019) Monoclonal anti-CD47 interference in red cell and platelet testing. Transfusion 59:730&#x02013;737. 10.1111/trf.15033<pub-id pub-id-type="pmid">30516833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>J</given-names></name><name><surname>Lau</surname><given-names>EYT</given-names></name><name><surname>So</surname><given-names>FTY</given-names></name><etal/></person-group><article-title>Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma</article-title><source>Liver Int</source><year>2016</year><volume>36</volume><fpage>737</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1111/liv.12963</pub-id><pub-id pub-id-type="pmid">26351778</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Lo J, Lau EYT, So FTY et al (2016) Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. Liver Int 36:737&#x02013;745. 10.1111/liv.12963<pub-id pub-id-type="pmid">26351778</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Kosaka</surname><given-names>A</given-names></name><name><surname>Ishibashi</surname><given-names>K</given-names></name><name><surname>Nagato</surname><given-names>T</given-names></name><etal/></person-group><article-title>CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes</article-title><source>J Exp Med</source><year>2021</year><pub-id pub-id-type="doi">10.1084/jem.20200792</pub-id><pub-id pub-id-type="pmid">34559187</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kosaka A, Ishibashi K, Nagato T et al (2021) CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. J Exp Med. 10.1084/jem.20200792<pub-id pub-id-type="pmid">34559187</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Sudani</surname><given-names>H</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><etal/></person-group><article-title>Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition</article-title><source>npj Precis Oncol</source><year>2023</year><volume>7</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41698-023-00418-4</pub-id><pub-id pub-id-type="pmid">36593350</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Al-Sudani H, Ni Y, Jones P et al (2023) Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition. npj Precis Oncol 7:1&#x02013;10. 10.1038/s41698-023-00418-4<pub-id pub-id-type="pmid">36593350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Kauder</surname><given-names>SE</given-names></name><name><surname>Kuo</surname><given-names>TC</given-names></name><name><surname>Harrabi</surname><given-names>O</given-names></name><etal/></person-group><article-title>ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><fpage>1</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0201832</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kauder SE, Kuo TC, Harrabi O et al (2018) ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS ONE 13:1&#x02013;33. 10.1371/journal.pone.0201832</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>H</given-names></name><name><surname>Qian</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Targeting CD47 enhances the efficacy of anti-PD-1 and CTLA-4 in an esophageal squamous cell cancer preclinical model</article-title><source>Oncol Res</source><year>2017</year><volume>25</volume><fpage>1579</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.3727/096504017X14900505020895</pub-id><pub-id pub-id-type="pmid">28337964</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Tao H, Qian P, Wang F et al (2017) Targeting CD47 enhances the efficacy of anti-PD-1 and CTLA-4 in an esophageal squamous cell cancer preclinical model. Oncol Res 25:1579&#x02013;1587. 10.3727/096504017X14900505020895<pub-id pub-id-type="pmid">28337964</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Pu</surname><given-names>Y</given-names></name><name><surname>Cron</surname><given-names>K</given-names></name><etal/></person-group><article-title>CD47 blockade triggers T cell-mediated destruction of immunogenic tumors</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><fpage>1209</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1038/nm.3931</pub-id><pub-id pub-id-type="pmid">26322579</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Liu X, Pu Y, Cron K et al (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21:1209&#x02013;1215. 10.1038/nm.3931<pub-id pub-id-type="pmid">26322579</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Deuse</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Agbor-Enoh</surname><given-names>S</given-names></name><etal/></person-group><article-title>The SIRP&#x003b1;-CD47 immune checkpoint in NK cells</article-title><source>J Exp Med</source><year>2021</year><pub-id pub-id-type="doi">10.1084/JEM.20200839</pub-id><pub-id pub-id-type="pmid">33416832</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Deuse T, Hu X, Agbor-Enoh S et al (2021) The SIRP&#x003b1;-CD47 immune checkpoint in NK cells. J Exp Med. 10.1084/JEM.20200839<pub-id pub-id-type="pmid">33416832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Chenchula</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Shodan Babu</surname><given-names>V</given-names></name></person-group><article-title>Comparative efficacy of 3dimensional (3D) cell culture organoids vs. 2dimensional (2D) cell cultures vs experimental animal models in disease modeling, drug development, and drug toxicity testing</article-title><source>Int J Curr Res Rev</source><year>2019</year><volume>11</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.31782/IJCRR.2019.11242</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Chenchula S, Kumar S, Shodan Babu V (2019) Comparative efficacy of 3dimensional (3D) cell culture organoids vs. 2dimensional (2D) cell cultures vs experimental animal models in disease modeling, drug development, and drug toxicity testing. Int J Curr Res Rev 11:11&#x02013;17. 10.31782/IJCRR.2019.11242</mixed-citation></citation-alternatives></ref></ref-list></back></article>